Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements

Osteoarticular Infection Clinical Trial

— PRODALBA  

Official title:

Efficacy of Dalbavancin in Osteoarticular Infections Associated With Hip and Knee Replacements

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05046860
• Other study ID #: 20-AOI-03
• Status: Recruiting
• Phase: N/A
• Start date: March 7, 2022
• Est. completion date: September 30, 2024

Study information

• Verified date: March 2024
• Source: Centre Hospitalier Universitaire de Nice
• Contact: Johan COURJON, MD
• Phone: 0492035452
• Email: courjon.j[@]chu-nice.fr
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Osteoarticular infections associated with hip and knee prostheses require optimal surgical and medical management to maximize the rate of therapeutic success. Antibiotic therapy should be administered for a period of 12 weeks. Tolerance problems, difficulties in maintaining compliance over 12 weeks, bacterial multidrug resistance and sometimes intravenous administration are the main obstacles to appropriate antibiotic therapy and to limiting iatrogenicity. Dalbavancin is an antibiotic derived from teicoplanin (glycopeptide) with a long half-life, of punctual parenteral administration without a central line, active on staphylococci, and well tolerated. The data in the literature concerning its efficacy in Osteoarticular infections associated with hip and knee prostheses are limited and heterogeneous. Investigators would like to describe its efficacy in a homogeneous series of patients in terms of the type of infection, their surgical management and the methods of administration of the product in order to extend its use.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 43
• Est. completion date: September 30, 2024
• Est. primary completion date: September 30, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Age greater than or equal to 18 years

• First monomicrobial osteoarticular infection of knee or hip prosthesis with staphylococcus sensitive to dalbavancin (determined by a minimum inhibitory concentration by microdilution of the strain in question for vancomycin less than or equal to 2mg/L) and rifampicin, treated surgically by debridement, antibiotics and implant retention with change of moving parts (acute infections) or change in 1 stage (chronic infections)

• Social security affiliation

• Signature of informed consent

Exclusion Criteria:

• Hypersensitivity to glycopeptides or rifampin or to any of the excipients

• Porphyrias

• Probabilistic antibiotic treatment not administered within 24 hours of surgery

• Probabilistic antibiotic treatment that did not take into account the bacterium causing the infection in its spectrum

• Acute hematogenous infection (acute secondary)

• Use of background treatment incompatible with the inducing effect of rifampicin (see Summary of Product Characteristics for rifampicin)

• Contraindications to rifampin therapy: Moderate to severe impairment of liver function, patients with a history of hypersensitivity to other rifamycins, porphyria.

Hepatic cirrhosis

• Use of ototoxic therapy, such as an aminoglycoside

• Renal function with glomerular filtration rate less than 30 ml/min as measured by MDRD (Modification of Diet in Renal Disease)

• Pregnant and breastfeeding women: at inclusion a blood pregnancy test will be performed for women of childbearing age. The results will be communicated to the patient by a physician of her choice.

• Women of childbearing age not using an effective method of contraception (pill, intrauterine device, vaginal ring, contraceptive skin patch, hormonal subcutaneous implant, surgical sterilization)

• Protected persons defined in the following articles of the public health code:

L. 1121-6: persons deprived of liberty by a judicial or administrative decision, persons hospitalized without consent and persons admitted to a health or social establishment for purposes other than research; L. 1121-8: adults subject to a legal protection measure or unable to express their consent; L. 1122-1-2: persons in emergency situations who are unable to give prior consent.

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Osteoarticular Infection

Intervention

Drug:
• Dalbavancin
The unit dose of dalbavancin administered via the peripheral venous route will be 1500 mg at each injection with a first injection at Day1, a second injection at Day15 and a third at Day36, which corresponds to 61 days of treatment with dalbavancin. In case of residual dalbavancin dosage at Day15 lower than 15 mg/L (rare situation) and a minimal inhibitory concentration for dalbavancin of 0.125mg/L (less than 5% of the strains), an injection every 14 days will be necessary, i.e. Day1, Day15, Day29, Day43 and Day57, which corresponds to 71 days of dalbavancin treatment. Rifampicin should be given orally at a dose of 600 mg on an empty stomach in the morning for patients weighing less than 70 kg and 900 mg on an empty stomach in the morning for patients weighing more than 70 kg.

Locations

Country	Name	City	State
France	AP-HP - Hôpital Ambroise-Paré	Boulogne-Billancourt
France	CHU de Nice	Nice
France	Centre Hospitalier de Tourcoing	Tourcoing
France	CHRU de TOURS	Tours

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	therapeutic success	therapeutic success defined by the absence of failure within 12 months of surgical management	12 months
Secondary	therapeutic success at 24 months	therapeutic success defined by the absence of failure within 24 months of surgical management	24 months
Secondary	Tolerance	Tolerance will be assessed by collecting adverse events during treatment with dalbavancin and rifampin classified according to Common Terminology Criteria for Adverse Events (version 5.0) within 6 months of its first administration.	6 months of first administration of dalbavancin
Secondary	Residual dalbavancin dosage	Residual dalbavancin dosage at Day61	Day 61 of first administration of dalbavancin